- ￥600
- Solarbio
- 北京
- IO02301
- 2025年07月23日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Stroe at -20℃，6 months.
- 保质期：
Stroe at -20℃，6 months.
- 英文名：
Oridonin(10mM in DMSO,Sterile）
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
28957-04-2
- 规格：
1ml
| 基本信息 | |
| CAS | No.28957-04-2 |
| 中文名称 | 冬凌草甲素(10mM in DMSO,无菌） |
| 英文名称 | Oridonin(10mM in DMSO,Sterile） |
| 分子式 | C20H28O6 |
| 分子量 | 364.43 |
| 溶解性 | 请根据自己的实验要求使用。 |
| 外观(性状) | 无菌溶液 |
| 储存条件 | Stroe at -20℃，6 months. |
| 靶点 | Akt |
| 通路 | PI3K/Akt/mTOR |
| 背景说明 | 是一种 AKT 抑制剂，具有抗肿瘤、抗菌、抗炎等生理活性，可用于相关研究。 |
| 生物活性 | Oridonin (NSC-250682)， a diterpenoid isolated from Rabdosia rubescens， acts as an inhibitor of AKT， with IC50s of 8.4 and 8.9 μM for AKT1 and AKT2; Oridonin possesses anti-tumor， anti-bacterial and anti-inflammatory effects.[1-2] |
| In Vitro | Oridonin is an ATP-competitive inhibitor of AKT with IC50s of 8.4 and 8.9 μM for AKT1 and AKT2， respectively. Oridonin (5， 10 or 20 μM) obviously inhibits the growth of KYSE70， KYSE410 and KYSE450 ESCC cells via targeting AKT1/2. Oridonin (10 or 20 μM) causes G2/M phase cell cycle arrest in KYSE70， KYSE410 and KYSE450 cells， and induces apoptosis in these three cell lines at 20 μM. In addition， Oridonin (5， 10 or 20 μM) in combination with cisplatin or 5-FU enhances the inhibition of esophageal squamous cell carcinoma (ESCC) cell growth[1]. Oridonin (0.1 and 1 μM) preferentially suppresses AKT/mTOR signaling. Oridonin (1 μM) also selectively suppresses growth of breast cancer cells with hyperactivation of AKT signaling[2]. |
| 细胞实验 | Oridonin (160 mg/kg， p.o.) shows significant reduction in the tumor growth without obvious weigh loss in SCID mice bearing EG9 and HEG18 tumor cells. Oridonin treatment also suppresses the expression of Ki-67， phosphorylated AKT， GSK-3β or mTOR in mice[1]. Oridonin (15 mg/kg， i.p.) impairs cell growth in breast cancer with hyperactivation of AKT signaling in nude mice[2]. |
| 细胞实验 | Cells are seeded (6×103 cells/well for KYSE70; 2.5×103 cells/well for KYSE410; 2×103 cells/well for KYSE450) in 96-well plates and incubated for 24 h and then treated with different amounts of Oridonin or vehicle. After incubation for 24， 48 or 72 h， cell proliferation is measured by the MTT assay. For anchorage-independent cell growth assessment， cells (2.5， 5 or 10 μM Oridonin) suspended in complete medium are added to 0.3% agar with vehicle， 2.5， 5 or 10 μM Oridonin in a top layer over a base layer of 0.5% agar with vehicle， 2.5， 5 or 10 μM Oridonin. The cultures are maintained at 37°C in a 5% CO2 incubator for 3 weeks and then colonies are visualized under a microscope and counted using the Image-Pro Plus software program[1]. |
| 动物实验 | Mice[2] Breast cancer cells are harvested and resuspended in 40% Matrigel-Basement Membrane Matrix， LDEV-free， and then injected (100 μL per site) into the fourth pair of mammary fat pads of nude mice (CrTac: NCr-Foxn1nu). Tumors are measured in two dimensions using manual calipers. Tumor volume is calculated using the formula: Volume = 0.5 × length × width × width. Tumor volume is measured every 2-3 days. Upon harvesting， tumors are fixed in formalin overnight and then in 70% ethanol for histopathology analysis. Mice are treated with Oridonin (15 mg/kg) in 1% Pluronic F68 or vehicle (1% Pluronic F68) daily by intraperitoneal (IP) injection. BEZ235 is reconstituted 1:9 in 1-methyl-2 pyrolidone and polyethylene glycol 300 (PEG300) Mice are treated with this compound formulation at 45 mg/kg daily (QD) by oral gavage[2]. |
| 激酶实验 | For the AKT kinase assay， the ADP-Glo? Kinase Assay Kit is used. Active AKT1 or AKT2 kinase and inactive GSK-3β as substrate are mixed by 1× reaction buffer and then added to a white 96-well plate. Pure ATP provided in the kit is serially diluted obtain a final concentration of 0， 1， 10， 50， and 100 μM. GSK-3β is added to reach a final concentration of 2.5， 5， 10 or 20 μM and DMSO is used as a control. The mixed solution is incubated at room temperature and luciferase activity is measured using the Luminoskan Ascent plate reader[1]. |
| 数据来源文献 | [1]. Song M， et al. Targeting AKT with oridonin inhibits growth of esophageal squamous cell carcinoma in vitro and patient derived xenografts in vivo. Mol Cancer Ther. 2018 Apr 25. pii: molcanther.0823.2017. [2]. Sun B， et al. Oridonin inhibits aberrant AKT activation in breast cancer. Oncotarget. 2018 Feb 1;9(35):23878-23889. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
含量成反比。 本试剂盒用于检测在GPCR激动剂刺激下活细胞或者细胞膜制备品产生的cAMP。对于偶联Gαs的受体，激动剂刺激导致665nm的荧光强度降低，而拮抗剂则可以逆转这一效应；对于偶联Gαi的受体，在激动剂刺激的同时用forskolin刺激cAMP产生，那么激动剂则抑制forskolin诱导的cAMP的生成，因此对照只给forskolin的细胞组可以通过665nm荧光强度的增加反应激动剂的效应。 该试剂盒的灵敏度很高，室温下反应在20h内是稳定的。本试剂
技术资料暂无技术资料 索取技术资料
IO02301 冬凌草甲素(10mM in DMSO,无菌） 抑制剂/拮抗剂/激动剂 索莱宝
￥600
